Home > News > Venture firms still don't see the nanotech in biosciences
October 1st, 2003
Venture firms still don't see the nanotech in biosciences
Timing is everything, say Oregon's venture fund managers. The state of nanotechnology in the biosciences is too early for venture capital investing, believes Gerry Langeler, of Seattle-based OVP Venture Partners, the oldest venture firm in the Pacific Northwest, currently with $195 million to invest.
Pixelligent Closes $5.5 Million in Funding: Capital Will Be Used to Support Global Customer Growth December 12th, 2014
Nanometrics Announces Upcoming Investor Events November 19th, 2014
Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014
Arrowhead to Present at Upcoming Conferences November 15th, 2014